Health Economics›Glioblastoma›Recurrent disease non-curative therapy non-randomized or retrospective data

Recurrent disease non-curative therapy non-randomized or retrospective data

Glioblastoma · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Bevacizumab Variant #01	—	R 20 420	28d	—	—	~2	~R 40 840 indirect	—
Irinotecan and Bevacizumab Variant #01	—	R 19 987	14d	—	—	~2	~R 39 975 indirect	—
Temozolomide monotherapy Variant #02	—	R 7 358	14d	~4.0 mo	~16.6 mo	~26	~R 129 994 PFS proxy · indirect	7
Irinotecan monotherapy Variant #01	—	R 2 716	42d	~2.3 mo	~8.5 mo	~11	~R 29 874 PFS proxy · indirect	19
Cyclophosphamide monotherapy Variant #01	—	R 1 680	28d	—	~15.8 mo	~1	~R 1 680 PFS proxy · indirect	1
CART-EGFRvIII monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Procarbazine monotherapy Variant #01 Partial	—	—	28d	—	—	~6	—	—

7 of 7 regimens shown